In another CF cohort (n=48) similarly treated, a significant reduction in plasma IL-8, IL-6 and IL-17A levels and a peripheral blood immune cell composition more reflective of healthy controls was observed [39]. The gene discussed is IL17A; the disease is cystic fibrosis.